|
Name |
Wakodecaline B
|
| Molecular Formula | C25H35NO6 | |
| IUPAC Name* |
(2R)-2-[[(2S,3R,3aS,5aR,7S,9aS,9bR)-4,7,9b-trimethyl-1-oxo-3-[(E)-3-oxobut-1-enyl]-3,3a,5a,6,7,8,9,9a-octahydro-2H-cyclopenta[a]naphthalene-2-carbonyl]-methylamino]-3-hydroxypropanoic acid
|
|
| SMILES |
C[C@H]1CC[C@H]2[C@H](C1)C=C([C@H]3[C@@]2(C(=O)[C@H]([C@@H]3/C=C/C(=O)C)C(=O)N(C)[C@H](CO)C(=O)O)C)C
|
|
| InChI |
InChI=1S/C25H35NO6/c1-13-6-9-18-16(10-13)11-14(2)21-17(8-7-15(3)28)20(22(29)25(18,21)4)23(30)26(5)19(12-27)24(31)32/h7-8,11,13,16-21,27H,6,9-10,12H2,1-5H3,(H,31,32)/b8-7+/t13-,16+,17-,18-,19+,20-,21+,25+/m0/s1
|
|
| InChIKey |
ARANVBSJVTTXRP-KGMUJOTPSA-N
|
|
| Synonyms |
Wakodecaline B
|
|
| CAS | NA | |
| PubChem CID | 139589498 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 445.5 | ALogp: | 2.1 |
| HBD: | 2 | HBA: | 6 |
| Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 112.0 | Aromatic Rings: | 3 |
| Heavy Atoms: | 32 | QED Weighted: | 0.369 |
| Caco-2 Permeability: | -5.359 | MDCK Permeability: | 0.00001230 |
| Pgp-inhibitor: | 0.133 | Pgp-substrate: | 0.006 |
| Human Intestinal Absorption (HIA): | 0.802 | 20% Bioavailability (F20%): | 0.687 |
| 30% Bioavailability (F30%): | 0.434 |
| Blood-Brain-Barrier Penetration (BBB): | 0.539 | Plasma Protein Binding (PPB): | 90.08% |
| Volume Distribution (VD): | 0.375 | Fu: | 7.79% |
| CYP1A2-inhibitor: | 0.023 | CYP1A2-substrate: | 0.114 |
| CYP2C19-inhibitor: | 0.039 | CYP2C19-substrate: | 0.761 |
| CYP2C9-inhibitor: | 0.058 | CYP2C9-substrate: | 0.609 |
| CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.123 |
| CYP3A4-inhibitor: | 0.028 | CYP3A4-substrate: | 0.276 |
| Clearance (CL): | 1.794 | Half-life (T1/2): | 0.816 |
| hERG Blockers: | 0.011 | Human Hepatotoxicity (H-HT): | 0.703 |
| Drug-inuced Liver Injury (DILI): | 0.983 | AMES Toxicity: | 0.015 |
| Rat Oral Acute Toxicity: | 0.336 | Maximum Recommended Daily Dose: | 0.844 |
| Skin Sensitization: | 0.624 | Carcinogencity: | 0.699 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.013 |
| Respiratory Toxicity: | 0.907 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003817 | ![]() |
0.809 | D0E9KA | ![]() |
0.275 | ||
| ENC005775 | ![]() |
0.527 | D04SFH | ![]() |
0.254 | ||
| ENC004322 | ![]() |
0.527 | D0G7KJ | ![]() |
0.245 | ||
| ENC004320 | ![]() |
0.448 | D0O5FY | ![]() |
0.242 | ||
| ENC004321 | ![]() |
0.448 | D0X7XG | ![]() |
0.235 | ||
| ENC005774 | ![]() |
0.448 | D0I5DS | ![]() |
0.234 | ||
| ENC004339 | ![]() |
0.413 | D0V2JK | ![]() |
0.233 | ||
| ENC005181 | ![]() |
0.393 | D06AEO | ![]() |
0.228 | ||
| ENC005182 | ![]() |
0.393 | D08BDT | ![]() |
0.228 | ||
| ENC003021 | ![]() |
0.391 | D09WYX | ![]() |
0.227 | ||